Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Scleroderma and alveolar inflammation]

B Crestani1, M Aubier

  • 1Unité INSERM 408, Faculté Xavier-Bichat, Paris.

Revue Des Maladies Respiratoires
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)].

Revue des maladies respiratoires·2025
Same author

[Low-dose methotrexate: Indications and side effects, particularly in cases of diffuse interstitial pneumonia].

Revue des maladies respiratoires·2024
Same author

Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same author

[Fibroblast growth factor (FGF) endocrines and pulmonary fibrogenesis].

Revue des maladies respiratoires·2023
Same author

[J2R 2022 back in Reims].

Revue des maladies respiratoires·2023
Same author

[Adipocytes, adipokines and metabolic alterations in pulmonary fibrosis].

Revue des maladies respiratoires·2023
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Scleroderma-associated pulmonary fibrosis involves activated immune cells in the lungs. Increased interleukin-8 in macrophages drives neutrophil inflammation and may contribute to lung damage and fibrosis.

Area of Science:

  • Immunology
  • Pulmonology
  • Rheumatology

Context:

  • Pulmonary fibrosis is a severe complication of scleroderma.
  • The underlying mechanisms of this lung involvement are not fully understood.
  • Inflammation involving alveolar macrophages and neutrophils is implicated.

Purpose:

  • To investigate the activation state of alveolar macrophages and circulating monocytes in scleroderma patients with lung involvement.
  • To compare these inflammatory markers with those in healthy individuals.

Summary:

  • Scleroderma patients with interstitial lung disease exhibit neutrophil alveolitis.
  • Alveolar macrophages in these patients secrete higher levels of interleukin-8, a neutrophil chemoattractant.
  • An imbalance in the elastase-antielastase system is observed, potentially contributing to alveolar damage and fibrosis.

Related Experiment Videos

  • Activated monocytes also show increased secretion of interleukin-6 and interleukin-8, indicating systemic inflammation.

    • Impact:

    • This study highlights the role of activated immune cells, particularly macrophages and neutrophils, in scleroderma-related pulmonary fibrosis.
    • Findings suggest a link between localized lung inflammation and broader systemic inflammation in scleroderma.
    • Understanding these inflammatory pathways could lead to new therapeutic targets for managing lung complications in scleroderma.